Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation

1 Jan 2019

Abstract excerpt

The BCR-ABL fusion protein with strong tyrosine kinase activity is one of the molecular biological bases of leukemia. Imatinib (Gleevec), a specific targeted drug for the treatment of chronic myeloid leukemia (CML), was developed for inhibiting the kinase activity of the BCR-ABL fusion protein. Despite the positive clinical efficacy of imatinib, the proportion of imatinib resistance has gradually increased. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Chronic Myeloid Leukemia Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31258755
DOI: 10.7150/jca.29528

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Regulatory Molecules and Corresponding Processes of BCR-ABL Protein DegradationPMID 31258755Read ↗

Protein degradation: expanding the toolbox to restrain cancer drug resistanceSemantic proximity Read ↗

Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinaseSemantic proximity Read ↗

Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.Semantic proximity Read ↗

Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.Semantic proximity Read ↗

Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cellsSemantic proximity Read ↗

Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleasesSemantic proximity Read ↗

RAPSYN-Mediated Neddylation of BCR-ABL Alternatively Determines the Fate of Philadelphia Chromosome-positive LeukemiaSemantic proximity Read ↗

PROTACs as Potential Therapeutic Agents for Cancer Drug ResistanceSemantic proximity Read ↗

Structure and dynamic regulation of Abl kinases.Semantic proximity Read ↗

Charting the molecular network of the drug target Bcr-AblSemantic proximity Read ↗

A common phosphotyrosine signature for the Bcr-Abl kinaseSemantic proximity Read ↗

The capable ABL: what is its biological function?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.